کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2106629 1083558 2010 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
How best to use new therapies in multiple myeloma
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
How best to use new therapies in multiple myeloma
چکیده انگلیسی

Advances in the molecular understanding of myeloma have led to the development of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (bortezomib). When used alone, these agents have significant activity against myeloma and responses increase significantly when they are combined with additional agents including glucocorticosteroids and chemotherapeutic agents such as alkylators. There is a drive to use these novel agents in patients with newly diagnosed myeloma, where they lead to impressive response rates with increasing duration of responses. In addition, novel agents are now the mainstays of therapy for relapsed disease. In the following paper, we summarize the key observations from recent completed and ongoing studies that determined the effect of these novel therapies both in the setting of newly diagnosed myeloma and for relapsed disease. We also discuss our approach to the use of these agents in specific myeloma settings.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Blood Reviews - Volume 24, Issue 3, May 2010, Pages 91–100
نویسندگان
, ,